CAS 1997338-61-0 Canagliflozin-[d4] - Isotope / BOC Sciences

General Information
Catalog: BLP-011203
CAS: 1997338-61-0
Molecular Formula: C24H21D4FO5S
Molecular Weight: 448.54

General Information

Catalog: BLP-011203

CAS: 1997338-61-0

Molecular Formula: C24H21D4FO5S

Molecular Weight: 448.54

Chemical Structure

Catalog Number	Size	Price	Stock	Quantity
BLP-011203	5 mg	$839	In stock

Catalog Number

Size

Price

Stock

Quantity

BLP-011203

5 mg

$839

In stock

Description	Canagliflozin D4 is a labelled Canagliflozin. Canagliflozin is a medication used for the treatment of type 2 diabetes.
Synonyms	(2S,3R,4R,5S,6R)-2-[3-({5-[4-fluoro(2,3,5,6-D4)phenyl]thiophen-2-yl}methyl)-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
IUPAC Name	(2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-[4-methyl-3-[[5-(2,3,5,6-tetradeuterio-4-fluorophenyl)thiophen-2-yl]methyl]phenyl]oxane-3,4,5-triol
Related CAS	842133-18-0 (unlabelled)
Canonical SMILES	CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
InChI	InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1/i4D,5D,6D,7D
InChI Key	XTNGUQKDFGDXSJ-OQRSEGJPSA-N
Purity	98% HPLC

Canagliflozin-[d4], a deuterium-labeled derivative of Canagliflozin, utilized for treating type 2 diabetes via inhibiting sodium-glucose co-transporter 2 (SGLT2). Here are the key applications of Canagliflozin-[d4]:

Pharmacokinetic Studies: Employing Canagliflozin-[d4] in pharmacokinetic investigations aids in tracing the drug's absorption distribution metabolism and excretion within the body. The deuterium label plays a pivotal role in distinguishing between the administered drug and its metabolites a critical aspect in comprehending the drug's efficacy and safety profile.

Metabolic Stability Testing: The presence of deuterium in Canagliflozin-[d4] facilitates the evaluation of Canagliflozin's metabolic stability by investigating the isotopic impact on the drug's degradation pathways. This analysis offers insights into how the drug's structure influences its metabolic breakdown valuable information for advancing drug development and optimizing pharmacokinetic properties.

Bioavailability Studies: Canagliflozin-[d4] is instrumental in bioavailability assessments aimed at comparing the absorption profiles of various formulations. Through monitoring the deuterated compound, researchers can gauge the efficiency of drug delivery systems a crucial step in refining formulations to achieve superior therapeutic outcomes.

Drug-Drug Interaction Research: Canagliflozin-[d4] plays a key role in exploring potential interactions with other pharmaceuticals. The deuterium label enables precise detection and quantification in complex biological matrices offering valuable insights into understanding and mitigating drug interactions essential for ensuring the safe co-administration of medications in clinical scenarios.